BCR-ABL inhibitor, also known by its CAS number 778270-11-4, is a medication used in the treatment of chronic myeloid leukemia (CML) and other types of cancer. It has gained attention in recent years due to its potential therapeutic benefits in inhibiting the activity of the BCR-ABL protein.
Introduce this product: BCR-ABL inhibitor is a type of targeted therapy that specifically targets the BCR-ABL protein, which is responsible for the rapid growth and proliferation of cancer cells in CML and other types of cancer. By inhibiting the activity of the BCR-ABL protein, BCR-ABL inhibitor can slow down or even halt the progression of cancer.
Chemical name: The chemical name of BCR-ABL inhibitor is (2Z)-2-butenedioic acid; N-[4-methyl-3-(4-pyridinyl)-2-thiazolyl]-4-[(4-methyl-1-piperazinyl)methyl]-, monosodium salt, trihydrate.
Molecular formula: The molecular formula of BCR-ABL inhibitor is C29H35N7NaO6S2.
Formula weight: The formula weight of BCR-ABL inhibitor is 665.76 g/mol.
CAS No: The CAS number of BCR-ABL inhibitor is 778270-11-4.
Top ten keywords from Google and Synonyms:
- Chronic myeloid leukemia
- Targeted therapy
- BCR-ABL protein
- Tyrosine kinase inhibitor
- Product mechanism
- Selective inhibitor
- Pharmaceutical compound
Synonyms for BCR-ABL inhibitor include nilotinib, Tasigna, and AMN107.
Health benefits of this product: BCR-ABL inhibitor has the potential to provide numerous health benefits in the treatment of CML and other types of cancer. By inhibiting the activity of the BCR-ABL protein, it can slow down or even halt the progression of cancer, leading to improved prognosis and quality of life.
Potential effects: The potential effects of BCR-ABL inhibitor are vast and varied. Its ability to selectively inhibit the activity of the BCR-ABL protein makes it a promising candidate for the treatment of CML and other types of cancer. Additionally, BCR-ABL inhibitor has shown promise in combination with other targeted therapies, improving treatment outcomes.
Product mechanism: BCR-ABL inhibitor works by selectively inhibiting the activity of the BCR-ABL protein, which is responsible for the rapid growth and proliferation of cancer cells in CML and other types of cancer. By inhibiting this protein, BCR-ABL inhibitor can slow down or even halt the progression of cancer.
Safety: BCR-ABL inhibitor has undergone extensive clinical trials and has been found to be safe and effective in the treatment of CML and other types of cancer. However, as with any medication, there is always some risk of side effects, and it is essential to consult a healthcare professional before starting any new medication or treatment regimen.
Side effects: Some potential side effects of BCR-ABL inhibitor may include nausea, diarrhea, and fatigue. Additionally, there is a potential risk of cardiovascular events and liver toxicity, so regular monitoring of cardiovascular function and liver function tests is necessary during treatment.
Dosing information: The dosing of BCR-ABL inhibitor will vary depending on the individual patient's medical condition, age, weight, and other factors. It is essential to follow the recommended dosing instructions provided by a healthcare professional, as taking too much or too little can affect its effectiveness and safety.
Conclusion: In conclusion, BCR-ABL inhibitor shows significant potential in treating CML and other types of cancer. As a targeted therapy, it provides greater specificity and fewer side effects than non-targeted treatments. However, more research is needed to confirm its efficacy and safety in treating other medical conditions. It is essential to consult a healthcare professional before starting any new medication or treatment regimen